Skip to main content

Table 3 Selected single nucleotide polymorphisms patient data

From: Prognostic and predictive factors in patients with metastatic or recurrent cervical cancer treated with platinum-based chemotherapy.

SNPs

No of patients (%)

p-value

ITP

IP

MDR1 C3435T

Polymorphisms

 CT

13 (59.1)

14 (66.6)

1

 CC

4 (18.2)

3 (14.3)

 

 TT

5 (22.7)

4 (19)

 

MDR1 G2677 T

Polymorphisms

 GT

5 (22.7)

5 (23.8)

0.904

 GG

15 (68.2)

13 (61.9)

 

 TT

2 (9.1)

3 (14.3)

 

ERCC1 C8092A

Polymorphisms

 CA

9 (40.9)

8 (38.1)

1

 CC

11 (50)

10 (47.6)

 

 AA

2 (9.1))

3 (14.3)

 

ERCC1 N118 N

Polymorphisms

 CT

8 (36.4)

12 (57.1)

0.371

 CC

3 (13.6)

3(14.3)

 

 TT

11 (50)

6 (28.6)

 
  1. ITP Ifosfamide Paclitaxel Cisplatin, IP Ifosfamide Cisplatin